

Common Hair and Nail Problems

Poonkiat Suchonwanit, MD


Hair and Scalp Disorders Unit Division of Dermatology Department of Medicine Ramathibodi Hospital

Hair problems

Hair loss



Hair haft abnormalities • Hair color



Excessive hair growth








Basic Hair Evaluation




The hair cycle







Anagen Catagen Telogen




10-15% 1-3 months



<1% 1-2 weeks

Normal hair shedding




Phase	Duration	Amount
Anagen	1000	90,000 (90%)
Telogen	100	10,000 (10%)
	Total	100,000

Abnormal hair shedding

>100 — Not wash

>200 — Wash





History taking

- Hair loss or hair thinning?
- Number of hair shedding?
- Characteristics?
- Duration?
- Life event?
- Symptom to indicate systemic disease?
- Family history?



Hair count




Hair & scalp examination

- Inspection
 - Distribution
 - Scalp lesions
- Hair pull test
- Tug test



Hair pull test



Tug test




Hair & scalp examination

- Distribution of hair loss
 - Localized
 - Diffuse
 - Pattern
- Hair shape: exclamation, tufted, fragility
- Scarring or non-scarring





Case 1



Case 2 and 3





Case 4 and 5





Scarring alopecia should be concerned

Non-scar vs Scar

Non-scarring alopecia
 Scarring alopecia






Permanent hair loss

Other areas

- Nail
- Oral cavity: mucosa, teeth
- Conjunctiva
- Thyroid gland
- Genitalia
- Other skin lesions








Approach to the patient with alopecia





ALOPECIA

NON-SCARRING

SCARRING


- Lichen planopilaris
- Lupus erythematosus
- Pseudopelade of Brocq
- Folliculitis decalvans
- Dissecting cellulitis of the scalp
- Morphea
- Trauma
- Tumor
- Infections

Common alopecia



Telogen effluvium

- Reaction to physical or mental stressors, drugs
- 3-6 mo. after inciting event
- Resolve after cause removed



Endocrine

Hypo- or hyperthyroidism

Postpartum

Peri- or postmenopausal state

Nutritional

Biotin deficiency

Caloric deprivation

Essential fatty acid deficiency

Iron deficiency

Protein deprivation

Zinc deficiency

Physical stress

Anemia

Surgery

Systemic illness

Psychological stress

Drugs (only those with incidence >1% noted her

Angiotension-converting enzyme inhibitors

Anticoagulants

Antimitotic agents (dose dependent)

Benzimidazoles

Beta blockers

Interferon

Lithium

Oral contraceptives

Retinoids

Valproic acid


Vitamin A excess

Anagen effluvium

- Loss of anagen hairs
- Usually broken off > shed
- Cause
 - Radiation therapy
 - Systemic chemotherapy
 - TOXIC agents
 - Severe protein malnutrition




Anagen effluvium




- Regrowth rapidly after stop chemotherapy
 - High-dose busulfan -> permanent alopecia

Alopecia areata





Pathophysiology




Lymphocyte accumulation

Hair shaft thinning




Multiple patches AA






Syphilitic alopecia

DDx in sexually active period






Alopecia totalis/universalis

Alopecia totalis (AT)



Alopecia universalis (AU)



Alopecia areata





- Nail:
 - pitting, trachyonychia, onychomadesis

Associated conditions

- Atopy
- Autoimmune thyroid disease
- Down syndrome
- Vitiligo
- Autoimmune polyendocrinopathy syndrome type I
- Type I diabetes (relative of AA pt.)
- SLE (Taiwan)

Management of AA

Treatment of Alopecia Areata

- Patchy alopecia
 - Intralesional corticosteroids: Up to 2 mL injected/session and repeated at intervals.
 - Potent topical steroid 1–2×/day.
 - Topical anthralin 0.1%—2.0% once daily.
 Wash off after 10—20 min, steadily increase contact duration, switch to higher dose if no significant irritation.
 - Minoxidil lotion (5%) twice daily.

Management of AA

- Extensive or rapidly progressive alopecia.
 - Contact immunotherapy.
 - Systemic corticosteroids. Benefits are uncertain and must be weighed against risk of systemic corticosteroid therapy.
 - Wig or hairpiece.
- Alopecia totalis/universalis
 - Contact immunotherapy.
 - Topical/systemic steroids.
 - Wig or hairpiece.

Prognosis


- Spontaneous remission (80% in 1 yr)
- Relapse is common
- Poor prognostic factor:
 - Location (ophiasis pattern)
 - Age of onset: childhood
 - Association of atopy
 - Duration of hair loss (>1 yr)
 - Loss of body hair
 - Nail involvement
 - Positive family history



Trichotillomania

- Bizarre shapes , irregular border
- Hairs of varying length





Trichotillomania

- Cognitive behavioral therapy: Most effective Rx
- Psychotropic drug :
 - 1st line: Clomipramine,
 SSRI (fluoxetine, sertaline)
 - NAC



Androgenetic alopecia




Male androgenetic alopecia



Female pattern hair loss

Male androgenetic alopecia






Female pattern hair loss






5 alpha reductase

- 5 alpha reductase enzyme
 - Key enzyme
 - Testosterone -> DHT



Randall: paradoxical effect of androgen



- Miniaturization
- Shortening of anagen duration
- Increased percentage of telogen

Management of AGA

Treatment of Androgenetic Alopecia

- Caution against unrealistic expectations;
 primary goal is to halt progression.
- Male pattern hair loss
 - <u>5% topical minoxidil</u> solution or foam twice daily.
 - Oral finasteride, 1 mg daily.
 - Combination of the above: Use for at least 6 mo to assess response, and continue treatment to maintain response.
 - Surgery (e.g., hair transplantation). Most useful for restoring frontal hair loss.

Minoxidil

- Topical only (solution or foam)
- 5% in male, 2-5% in female
- Twice daily
- Mechanism?
 - Unknown
- Side effect
 - Allergic contact dermatitis: propylene glycol
 - Irritant contact dermatitis: alcohol



Pitfall: use of systemic minoxidil









Finasteride

- Type II 5α reductase inhibitor
- 1 mg/day (Propecia)
- ½ AD or ¼ OD (Proscar)
- Sexual adverse effect
- Reduction incidence of prostate CA but small increase high grade prostate CA





Type II 5α Reductase



Dutasteride


- Type I & II 5α reductase inhibitor
- More potent & more half life time
- Efficacy -> in research
 - Evidence of mark decrease DHT level
 - Evidence of improve AGA
- Current use in BPH

Management of AGA


- Female pattern hair loss
 - 2%—5% topical minoxidi solution twice daily.
 - Topical 17β-estradiol (e.g., estradiol benzoate, 20–25 mg/mL isopropanol).
 - Oral anti-androgens (spironolactone, cyproterone acetate).
 - Combination of the above: Use for at least 6 mo to assess response, and continue treatment to maintain response.
 - Maintain serum ferritin > 40 μg/L.
 - Hair transplantation in selected cases.

Pitfall: use of 5 alpha-reductase inhibitor in female

- Teratogenic effect
 - Feminization in male fetus
 - No risk to a male fetus in a pregnant partner



Hair transplantation



Scarring alopecia



Characteristics

- Permanent destruction of the hair follicle
- Irreversible damage to hair follicle stem cell
- Effacement of follicular orifices

Discoid lupus erythematosus







pigmentary change, central atrophy



round, scaly- adherent scales, follicular plugging

Discoid lupus erythematosus

- Risks to develop SLE
 - 1. Widespread DLE below the neck
 - 2. Non-specific lesions
 - Alopecia
 - Vasculitis
 - 3. ANA positive high titer
 - 4. Lymphocytopenia

Treatment of CCLE

- Topical therapy
 - Sunscreen
 - Potent topical/intralesional steroid
- Systemic therapy
 - Antimalarial drugs
 - Methotrexate
 - Dapsone
 - Thalidomide



Lichen planopilaris

- Lichen planus of the scalp
- Evidence of lichen planus elsewhere
- Screening for HCV









Reticulated whitish patch



Pterygium nail



Twenty nails dystrophy

Treatment of LPP


- Mild to moderate LPP (<10%)</p>
 - Intralesional steroid (+/- topical steroid)
 - Oral steroid for rapid progressive
- Severe LPP (>10%)
 - Hydroxychloroquine
 - Cyclosporine

Nail problems




Nail problems

- Contour
- Surface
- Color
- Periungual
- Detachment



Structure of nail



Contour

- Clubbing
- Koilonychia
- Over curvature



Clubbing





- Intrathoracic disorder
- Hypertrophic pulmonary osteoarthropathy
 - Pachydermoperiostosis
- Secondary lung carcinoma

Koilonychia





- Spoon nail
- Physiologic in early infancy
- Iron deficiency

Pincer nail



Over curvature



Surface

- Beau's line
- Pits
- Trachyonychia



Beau's lines

- Transverse depression of nail plate
- Occur after illnesses






Nail pitting





Nail pitting



- Alopecia areata
 - Shallow regular pitting

Trachyonychia

Twenty nail dystrophy




Color

- Leukonychia
 - True leukonychia
 - Apparent leukonychia
- Chromonychia




Leukonychia

- True leukonychia
 - Transverse: systemic disorder
 - Punctate: manicure
 - Longitudinal
- Apparent leukonychia
 - Terry's nail
 - Half and half nail
 - Muehrcke's nail



White spots (leukonychia punctata)



White superficial onychomycosis



Terry's nail

- Associated with
 - Cirrhosis of the liver
 - Chronic congestive heart failure
 - Adult-onset diabetes mellitus



Half-and-half nail

- Two parts showing a sharp demarcation
- Uremic patients



Muehrcke's nail

- Paired, narrow white bands parallel the lunula in the nail bed
- Associated with
 - Hypoalbuminemia
 - Following chemotherapy





Fig 8. Oil-drop sign of the toenails.




Fig 9. Salmon-colored spots of the fingernails

Longitudinal melanonychia



Hutchinson's sign



 Extension of pigmentation onto the nail folds is a classic sign of subungual melanoma

Green nail



Pseudomonas nail infection

Splinter hemorrhages



Trauma (subungual hematoma)



Periungual

- Acute paronychia
- Chronic paronychia
- Dorsal pterygium
 - Gradual shortening of proximal nail groove
- Ventral pterygium
 - Obliterating distal nail groove

Acute paronychia





Chronic paronychia




Ingrown nail



Dorsal pterygium (Lichen planus)





Ventral pterygium



Faulty detachment

- Onychomadesis
 - Nail shedding
- Onycholysis
 - Detached distal or lateral attachment

Onychomadesis



Onycholysis

- Environmental
 - Exposures, irritants, water, photo onycholysis
- Primary skin disorder
 - Psoriasis
- Infection
 - Candidas, dermatophytes

- Drugs
 - Tetracyclines

- Metabolic/systemic disorder
 - Hyperthyroidism
- Tumor
 - Subungual exostoses, SCC



Fig 10. Onycholysis of the fingernails.

Onycholysis: secondary infection




Onycholysis: trauma




Onychomycosis

4 types




Distal subungual onychomycosis



White superficial onychomycosis



Proximal subungual onychomycosis



Treatment of onychomycosis

- Systemic antifungal drug: azole group, terbinafine
- Onychomycosis of toenails
 - Oral itraconazole
 - 200 mg PO BID for 1 week, then 3 weeks without treatment, repeated for a total of 4-6 pulses of therapy
- Onychomycosis of fingernails
 - Oral itraconazole
 - 200 mg PO BID for 1 week, then 3 weeks without treatment, then
 200 mg PO BID for 1 week (2-4 pulses)



THANK YOU